Early drug discovery begins with hypotheses. A medicinal chemist draws a compound expecting a structural feature to occupy a hydrophobic pocket, improve metabolic stability, or increase selectivity over an off-target. Before synthesis, support usually comes from structural reasoning, published SAR for similar chemical series, and experience with the target class. After synthesis, experimental data confirm or reject the hypothesis. The interval from drawing the compound to receiving the answer is the hypothesis-data gap.
The hypothesis-data gap is more than a delay. It is a decision cost. Each week spent awaiting confirmation keeps resources committed to a direction that may be wrong. Compressing the gap, or pre-testing hypotheses before synthesis, is a direct way for a discovery team to move faster without increasing its compound budget.
Where the gaps are
In a typical structure-based discovery campaign, the largest scaffold exploration gaps concern binding mode, physicochemical properties, and selectivity. Does a structural change shift the binding pose as expected? Does a substitution pattern create ADMET liabilities that would otherwise emerge downstream? Does the compound interact unintentionally with structural homologs of the target?
Binding mode questions are especially suited to early computational analysis. A compound designed for a hydrophobic pocket can be docked in minutes. An expected interaction supports the hypothesis with a consistent computational model, giving synthesis more than intuition alone. If the model shows no expected interaction, the compound may not fit as expected, may adopt a pose lacking the designed contact, or may expose a limitation in the model. In each case, the pre-synthesis check provides useful information.
Physicochemical questions fall into two groups. Purely computational properties, including logP, TPSA, molecular weight, and hydrogen bond counts, can be calculated instantly from structure with essentially no added evaluation time. ML-based properties, including Caco-2 permeability, CYP inhibition, and hERG binding, can also be predicted in minutes, though their reliability has caveats. Both are available before synthesis. The key question is whether the workflow makes checking them easy at that point.
Selectivity is harder to assess computationally without dedicated off-target screens, each requiring receptor preparation and docking setup. For common concerns, such as kinase selectivity panels, CYP isoform profiles, and hERG channel effects, computational pre-screens are standard practice. Less predictable off-target effects are less suitable for computation and require early experimental profiling.
What computation fills affordably, and what it does not
Computational tools are most useful when a fast, imperfect answer is more valuable than a slow, definitive one. This describes most scaffold exploration questions, where the aim is to narrow the hypothesis space rather than confirm one compound. A docking screen that identifies three of twelve proposed compounds with favorable binding mode predictions remains useful at 70 percent accuracy, because those three are a more informed bet than a random choice.
Computation fills affordably: binding mode predictions for standard drug-like scaffolds against well-characterized targets, physicochemical calculations across large series, ADMET flags for high-reliability endpoints such as solubility, logP, hERG alerts, and CYP structural alerts, plus relative ranking of series by predicted selectivity when off-target structures are available. These cover most information gaps arising during scaffold exploration, the highest-volume decision stage in early discovery.
Computation does not fill affordably: quantitative affinity differences between closely related analogs, which require FEP or an equivalent and are costly per compound pair; in vivo PK properties, which require PK experiments; mechanism-based toxicity, which requires dedicated mechanistic assays; and target engagement, which requires SPR, ITC, or cellular engagement assays. Current tools are too inaccurate, slow, or structurally limited to replace data for these questions. Using them this way produces systematically misleading conclusions.
Decision latency and its implications
Computational information helps only when the workflow provides it at the right decision point. A team that runs docking only when a computational colleague has capacity, or uses outputs mainly to rationalize synthesis decisions already made, is not receiving the full value of its tools.
The highest-value pattern makes a computational pre-check a standard part of synthesis planning, not an optional annotation completed when time permits. This is a workflow design issue, not a capability issue. A docking screen can run in a few hours. The question is whether it appears before it can change the synthesis decision, or only as a note added after synthesis is underway.
For growing discovery teams creating a computational workflow for the first time, the durable setup keeps the barrier to a pre-synthesis check low enough for it to become the default. Not every compound needs full docking. But when medicinal chemistry rationale rests on a structural binding mode hypothesis, checking it before synthesis is standard industry practice worth adopting early.
